lunedì, 4 maggio 2026

Notizie AIOM – anno XVII

Questions & answers: EU actions to prevent medicine shortages due to Brexit

March 26, 2019 - EMA has published a questions-and-answers (Q&A) document for patients, healthcare professionals and the general public on the preparatory work that European Union authorities are doing to prevent medicine shortages due to the United Kingdom’s withdrawal ...
Leggi tutto

New EudraVigilance system improves reporting of side effects and detection of safety signals

March 27, 2019 - The new and improved EudraVigilance, the European system for managing and analysing information on suspected adverse reactions to medicines that are authorised or being studied in clinical trials in the EU, received more than 2 million reports of suspected ...
Leggi tutto

EU Application Filed for Daratumumab in Newly Diagnosed, Transplant-Eligible Myeloma

March 27, 2019 - A Type II variation application has been submitted to the European Medicines Agency for the 4-drug regimen of daratumumab, bortezomib, thalidomide, and dexamethasone as a treatment for patients with newly diagnosed multiple myeloma who are eligible to undergo ...
Leggi tutto

20 years of sampling and testing programme for medicines authorised for the EU

March 28, 2019 - EMA and the European Directorate for the Quality of Medicines & Healthcare (EDQM) have reviewed EMA’s sampling and testing programme for centrally authorised medicines on the EU/EEA market, which has been organised yearly since 1998. The number ...
Leggi tutto

21 marzo 2019 – Nota Informativa Importante su Belatacept (Bristol-Myers Squibb)

Knowledge and use of biosimilars in oncology: a survey by the European Society for Medical Oncology

Biosimilars can potentially improve the sustainability of cancer care; however, uptake is sometimes limited by safety concerns and a lack of understanding of the concept of extrapolation. The European Society for Medical Oncology (ESMO) conducted a survey to assess the current ...
Leggi tutto

Scheda informativa condivisa da ISS, PMA, AIMAC e AIOM

Suggerimenti semplici su come preservare la fertilità prima dei trattamenti antitumorali, firmate da Istituto Superiore di Sanità (ISS), Registro Nazionale di Procreazione Medicalmente Assistita (PMA), Associazione Italiana Malati di Cancro, parenti e amici ...
Leggi tutto

Dal Soroptimist International Club Genova a favore delle ragazze STEM

Il Premio, del valore di 2.000 Euro, sarà attribuito ad una Tesi di Laurea Magistrale in campo Emato-Oncologico, discussa da una studentessa dell’Università degli Studi di Genova negli anni accademici 2016-17 o 2017-18, in una delle seguenti discipline: ...
Leggi tutto

Financial Toxicity in Advanced and Metastatic Cancer: Overburdened and Underprepared

Patients with metastatic or advanced cancer are likely to be particularly susceptible to financial hardship for reasons related both to the characteristics of metastatic disease and to the characteristics of the population living with metastatic disease. First, metastatic ...
Leggi tutto

Localization of distant metastases defines prognosis and treatment efficacy in patients with FIGO stage IV ovarian cancer

Patients with ovarian cancer who are diagnosed with Federation of Gynecology and Obstetrics (FIGO) stage IV disease are a highly heterogeneous group with possible survival differences. The FIGO staging system was therefore updated in 2014. To evaluate the 2014 changes to ...
Leggi tutto